Castle Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Cash & Equivalents	98.84	122.95	329.63	409.85	98.85	4.48	1.21
Short-Term Investments	144.26	135.68	0	0	0	0	0
Cash & Cash Equivalents	243.1	258.63	329.63	409.85	98.85	4.48	1.21
Cash Growth	-6.00%	-21.54%	-19.57%	314.64%	2106.85%	269.54%	-
Receivables	39.49	24.56	18.59	13.86	15.52	14.62	6.21
Inventory	7.94	3.98	2.02	2.22	1.24	0.88	0.3
Other Current Assets	5.1	5.12	3.5	3.67	1.08	-1.86	-1.05
Total Current Assets	295.64	292.29	353.74	429.59	116.68	18.13	6.68
Property, Plant & Equipment	37.74	26.5	16.88	7.1	2.06	1.53	1.47
Goodwill and Intangibles	117.34	126.35	88.92	0	0	0	0.04
Other Long-Term Assets	2.63	2.2	3.02	2.63	1.01	2.75	1.63
Total Long-Term Assets	157.71	155.04	108.83	9.73	3.07	4.28	3.14
Total Assets	453.34	447.33	462.57	439.33	119.75	22.41	9.82
Accounts Payable	10.27	4.73	2.55	2.1	1.87	1.45	1.12
Deferred Revenue	0	0	0	8.35	0	0	0
Current Debt	1.14	1.78	1.18	0	5.83	0	1
Other Current Liabilities	36.26	29.62	21.16	10.43	7.59	5.29	3.1
Total Current Liabilities	47.67	36.13	24.89	20.88	15.29	6.74	5.22
Long-Term Debt	14.17	11.53	6.9	0	19.29	24.5	17.6
Other Long-Term Liabilities	0.23	0.52	19.05	2.76	0.06	1.24	1.27
Total Long-Term Liabilities	14.4	12.05	25.95	2.76	19.34	25.74	18.87
Total Liabilities	62.07	48.18	50.83	23.64	34.63	32.48	24.09
Total Debt	15.31	13.31	8.08	0	25.12	24.5	18.6
Debt Growth	15.03%	64.75%	-	-	2.54%	31.70%	-
Retained Earnings	-218.37	-160.91	-93.77	-62.5	-52.21	-57.49	-51.12
Comprehensive Income	0.14	-0.38	0	0	0	0	0
Shareholders' Equity	391.27	399.15	411.74	415.69	85.11	-56.57	-50.31
Net Cash / Debt	227.79	245.32	321.55	409.85	73.72	-20.02	-17.39
Net Cash / Debt Growth	-7.14%	-23.71%	-21.54%	455.94%	-	-	-
Net Cash Per Share	8.50	9.42	12.79	21.65	8.52	-10.50	-9.17
Working Capital	247.97	256.16	328.86	408.72	101.39	11.39	1.46
Book Value Per Share	14.60	15.32	16.38	21.96	9.91	-29.68	-26.54

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).